Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
June 17, 2008

Boehringer Ingelheim to Acquire Actimis Pharmaceuticals for $515M

  • Boehringer Ingelheim will acquire Actimis Pharmaceuticals through a structured buyout in which Boehringer Ingelheim will acquire shares of Actimis depending on the achievement of several successive milestones with Actimis’ leading asthma compound AP768.

    If AP768, currently in Phase I development, is successfully advanced into a Phase III, Boehringer Ingelheim will own 100% of Actimis’ shares. Upon successful completion of the entire development program, the total deal will be worth $515 million. 

    AP768 interacts with CRTH21, a target for asthma and allergic rhinitis. Previous to the currently ongoing Phase I trial, the compound was shown to have a more effective mechanism of action across multiple available animal models compared to currently marketed leukotriene receptor antagonists, according to the companies.

    Related Links:

    Researchers Discover SNP Linked to Asthma

    Using Multi-Pathway Target Knockdown

    Managing Asthma and COPD Treatments

  • You’re all set! Thank you for subscribing to GEN Highlights.